### Metro-Minnesota Community Oncology Research Consortium

#### Ovarian Cancer Clinical Research Trials

Studies currently open to accrual:

<table>
<thead>
<tr>
<th>Study ID</th>
<th>Title</th>
<th>Targeted Disease</th>
<th>Treatment line Description</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>NRG-GY007</td>
<td>Ruxolitinib with front-line neoadjuvant &amp; post-surgical therapy (NCT# 02713386)</td>
<td>Stage III or IV ovarian Cancer</td>
<td>untreated and plan to have chemotherapy with tumor reductive surgery</td>
<td>Tests an oral JAK inhibitor (Ruxolitinib) with Paclitaxel and Carboplatin</td>
</tr>
<tr>
<td>NRG-GY005</td>
<td>Cediranib + Olaparib vs. Olaparib alone vs. Standard of Care (NCT# 02502266)</td>
<td>Platinum resistant recurrent cancer (recurred within 6 months of chemo)</td>
<td>2nd line or greater</td>
<td>Tests how well a VEGF inhibitor Cediranib (Recentin) and a PARP inhibitor Olaparib (Lynparza) work when given together or separately</td>
</tr>
<tr>
<td>NRG-CC004</td>
<td>Bupropion in improving sexual desire in women with GYN cancer (NCT# 03180294)</td>
<td>Any gynecologic or breast cancer</td>
<td>Completed all surgery, chemo and/or radiation &gt; 6 months ago</td>
<td>Tests how well bupropion hydrochloride (Wellbutrin) works in improving sexual desire compared to placebo</td>
</tr>
<tr>
<td>(Monticello only) MNCC004</td>
<td>Nasal Vestibulitis Natural History Evaluation (Minnesota Cancer Clinical Trials Network: <a href="http://www.cancer.umn.edu/mncctn">www.cancer.umn.edu/mncctn</a>)</td>
<td>Any disease requiring chemotherapy</td>
<td>First line</td>
<td>Complete questionnaires at baseline, with each dose of chemotherapy and one month following chemotherapy to determine which chemo drugs are related to nasal symptoms</td>
</tr>
<tr>
<td>GOG3020</td>
<td>ATHENA: Rucarparib + Nivolumab (NCT# 03522246)</td>
<td>Stage III or IV ovarian cancer</td>
<td>After response to front line platinum-based chemotherapy</td>
<td>Compares Rucarparib (Rubraca) PARP inhibitor or placebo + Nivolumab (Opdivo) immunotherapy or placebo as maintenance treatment</td>
</tr>
</tbody>
</table>

Study details for NCT # at [https://clinicaltrials.gov/](https://clinicaltrials.gov/)

Contact MMCORC for more information at 952-993-1517 or [mmcorc.org](http://mmcorc.org)
<table>
<thead>
<tr>
<th>Metro-Minnesota Community Oncology Research Consortium</th>
<th>Ovarian Cancer Clinical Research Trials</th>
</tr>
</thead>
<tbody>
<tr>
<td>Studies pending and will open to accrual in the future:</td>
<td></td>
</tr>
</tbody>
</table>

**(Upcoming) NRG-GY019: Letrozole with or without Paclitaxel and Carboplatin (NCT# 04095364)**
- **Targeted Disease:** Newly diagnosed Stage II-IV low-grade serous ovarian cancer
- **Treatment line:** following cytoreductive surgery
- Tests how well letrozole (enzyme inhibitor that lowers estrogen levels) works with or without paclitaxel/carboplatin
- **Principal Investigator:** Dr. Jessica Thomes Pepin

**(Suspended) NRG-GY009: Pegylated Liposomal Doxorubicin Hydrochloride with Atzeolizumab and/or Bevacizumab (NCT# 02839707)**
- **Targeted Disease:** platinum-resistant recurrent ovarian cancer (recurred within 6 months of chemo)
- **Treatment line:** 2nd line or greater
- Tests the addition of Atezolizumab immunotherapy to pegylated liposomal doxorubicin hydrochloride with or without Bevacizumab
- **Principal Investigator:** Dr. Jessica Thomes Pepin

**(Suspended) ECOG-ACRIN EAE161: Computed Tomography Perfusion Imaging in Predicting Outcomes in Patients with Ovarian Cancer receiving Bevacizumab (NCT# 03412630)**
- **Targeted Disease:** platinum-resistant recurrent or persistent epithelial ovarian cancer
- **Treatment line:** First line
- Tests how well computed tomography (CT) perfusion imaging works in predicting outcomes in patients receiving bevacizumab
- **Principal Investigator:** Dr. David King

**(Suspended) NRG-GY016: Pembrolizumab + Epacadostat (NCT# 03602586)**
- **Targeted Disease:** recurrent or persistent clear cell ovarian cancer
- **Treatment line:** 2nd, 3rd, or 4th
- Tests combination of Pembrolizumab (Keytruda) immunotherapy with Epacadostat (inhibitor of enzymes needed for cell growth)
- **Principal Investigator:** Dr. Jessica Thomes Pepin

**(Suspended) NRG-GY014: Tazemetostat (NCT# 03348631)**
- **Targeted Disease:** platinum-resistant recurrent or persistent ovarian endometrioid or clear cell cancer
- **Treatment line:** 2nd, 3rd, or 4th
- Tests how well Tazemetostat (works to stop growth of tumor cells)
- **Principal Investigator:** Dr. Jessica Thomes Pepin

Study details for NCT # at [https://clinicaltrials.gov/](https://clinicaltrials.gov/)
Contact MMCORC for more information at 952-993-1517 or [mmcorc.org](http://mmcorc.org)